Skip to main content

Advertisement

Table 2 Distribution of primary and secondary study endpoints as well as preservation solutions to the different eras, 2554 patients from the Hannover liver transplant program

From: Comparable outcome of liver transplantation with Histidine-Tryptophan-Ketoglutarate vs. University of Wisconsin preservation solution: a retrospective observational double-center trial

  Era
I II III IV p-value
n (%) 346 (13.5%) 773 (30.3%) 811 (31.8%) 624 (24.4%) n.a.
HTK 32 (9.2%) 470 (60.8%) 439 (54.1%) 522 (83.7%) <0.0011
UW 314 (90.8%) 303 (39.2%) 372 (45.9%) 102 (16.3%) <0.0011
3 months mortality 82 (23.7%) 142 (18.4%) 112 (13.8%) 98 (15.7%) <0.0011
graft loss 224 (64.7%) 374 (48.4%) 281 (34.6%) 171 (27.4%) <0.0011
3 month graft survival 238 (68.8%) 582 (75.3%) 645 (79.5%) 482 (77.4%) 0.0011
HAT 14 (4.0%) 19 (2.5%) 30 (3.8%) 37 (6.0%) 0.0101
Portal vein thrombosis 6 (1.9%) 7 (0.9%) 24 (3.1%) 27 (4.4%) 0.0011
Caval vein thrombosis 1 (0.3%) 4 (0.5%) 10 (1.3%) 31 (5.0%) <0.0011
Post-operative hemorrhage 73 (22.7%) 197 (25.9%) 162 (20.8%) 169 (27.3%) 0.0201
Biliary complications 34 (16.9%) 127 (16.7%) 169 (21.7%) 138 (22.3%) 0.0151
Mean LOS in days (SD) 44 (34) 40 (30) 41 (35) 51 (43) <0.0012
  1. HTK = Histidine-Tryptophane-Ketoglutarate solution; UW = University of Wisconsin solution; SD = Standard Deviation; HAT = hepatic artery thrombosis; LOS = length of hospital stay.
  2. 1Pearson’s Chi2 Test.
  3. 2ANOVA.